Enhancing vaginal care through molecular diagnosis: HPV, STIs, and vaginitis
Genotyping for HPV16/18 is offered routinely in the national cervical cancer screening program in specific countries; besides, several new factors have recently garnered the attention that can enhance the protection against cervical cancer. A current approved second-generation vaccine has been approved to protect against HPV16/18 and other high-risk HPV types, which are also causally implicated in cervical cancer and HPV-related disease. Accordingly, studying the epidemiological distribution of high-risk HPV types and the vaginal environment infected with HPV becomes an essential factor in vaginal management. It is necessary to consider the effects of sexually transmitted infection (STI) and vaginitis on HPV infection. Experts will share their knowledge and experience about enhancing vaginal care by researching HPV, STI, and vaginitis in their respective fields in this symposium.
Chair: Hélène Peré, Hôpital Européen Georges-Pompidou (France)